CHAPTER 6: HOUSING FINANCE MARKET, BY REGION
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key trends and opportunities
6.2.2 North America Market size and forecast, by Application
6.2.3 North America Market size and forecast, by Providers
6.2.4 North America Market size and forecast, by country
6.2.4.1 U.S.
6.2.4.1.1 Market size and forecast, by Application
6.2.4.1.2 Market size and forecast, by Providers
6.2.4.2 Canada
6.2.4.2.1 Market size and forecast, by Application
6.2.4.2.2 Market size and forecast, by Providers
6.3 Europe
6.3.1 Key trends and opportunities
6.3.2 Europe Market size and forecast, by Application
6.3.3 Europe Market size and forecast, by Providers
6.3.4 Europe Market size and forecast, by country
6.3.4.1 Germany
6.3.4.1.1 Market size and forecast, by Application
6.3.4.1.2 Market size and forecast, by Providers
6.3.4.2 United Kingdom
6.3.4.2.1 Market size and forecast, by Application
6.3.4.2.2 Market size and forecast, by Providers
6.3.4.3 France
6.3.4.3.1 Market size and forecast, by Application
6.3.4.3.2 Market size and forecast, by Providers
6.3.4.4 Italy
6.3.4.4.1 Market size and forecast, by Application
6.3.4.4.2 Market size and forecast, by Providers
6.3.4.5 Spain
6.3.4.5.1 Market size and forecast, by Application
6.3.4.5.2 Market size and forecast, by Providers
6.3.4.6 Netherlands
6.3.4.6.1 Market size and forecast, by Application
6.3.4.6.2 Market size and forecast, by Providers
6.3.4.7 Rest of Europe
6.3.4.7.1 Market size and forecast, by Application
6.3.4.7.2 Market size and forecast, by Providers
6.4 Asia-Pacific
6.4.1 Key trends and opportunities
6.4.2 Asia-Pacific Market size and forecast, by Application
6.4.3 Asia-Pacific Market size and forecast, by Providers
6.4.4 Asia-Pacific Market size and forecast, by country
6.4.4.1 China
6.4.4.1.1 Market size and forecast, by Application
6.4.4.1.2 Market size and forecast, by Providers
6.4.4.2 India
6.4.4.2.1 Market size and forecast, by Application
6.4.4.2.2 Market size and forecast, by Providers
6.4.4.3 Japan
6.4.4.3.1 Market size and forecast, by Application
6.4.4.3.2 Market size and forecast, by Providers
6.4.4.4 Australia
6.4.4.4.1 Market size and forecast, by Application
6.4.4.4.2 Market size and forecast, by Providers
6.4.4.5 Singapore
6.4.4.5.1 Market size and forecast, by Application
6.4.4.5.2 Market size and forecast, by Providers
6.4.4.6 Rest of Asia-Pacific
6.4.4.6.1 Market size and forecast, by Application
6.4.4.6.2 Market size and forecast, by Providers
6.5 LAMEA
6.5.1 Key trends and opportunities
6.5.2 LAMEA Market size and forecast, by Application
6.5.3 LAMEA Market size and forecast, by Providers
6.5.4 LAMEA Market size and forecast, by country
6.5.4.1 Latin America
6.5.4.1.1 Market size and forecast, by Application
6.5.4.1.2 Market size and forecast, by Providers
6.5.4.2 Middle East
6.5.4.2.1 Market size and forecast, by Application
6.5.4.2.2 Market size and forecast, by Providers
6.5.4.3 Africa
6.5.4.3.1 Market size and forecast, by Application
6.5.4.3.2 Market size and forecast, by Providers
List of Tables
Table 1. Global Mrna Vaccines and Rnai Therapeutics Market, by Disease Type, 2021-2031 ($Million)
Table 2. Mrna Vaccines and Rnai Therapeutics Market Size, for Hereditary Transthyretin-Mediated Amyloidosis Genetic, by Region, 2021-2031 ($Million)
Table 3. Mrna Vaccines and Rnai Therapeutics Market for Hereditary Transthyretin-Mediated Amyloidosis Genetic by Country, 2021-2031 ($Million)
Table 4. Mrna Vaccines and Rnai Therapeutics Market Size, for Acute Hepatic Porphyria, by Region, 2021-2031 ($Million)
Table 5. Mrna Vaccines and Rnai Therapeutics Market for Acute Hepatic Porphyria by Country, 2021-2031 ($Million)
Table 6. Mrna Vaccines and Rnai Therapeutics Market Size, for Primary Hyperoxaluria Type 1, by Region, 2021-2031 ($Million)
Table 7. Mrna Vaccines and Rnai Therapeutics Market for Primary Hyperoxaluria Type 1 By Country, 2021-2031 ($Million)
Table 8. Mrna Vaccines and Rnai Therapeutics Market Size, for Atherosclerotic Cardiovascular Disease, by Region, 2021-2031 ($Million)
Table 9. Mrna Vaccines and Rnai Therapeutics Market for Atherosclerotic Cardiovascular Disease by Country, 2021-2031 ($Million)
Table 10. Global Mrna Vaccines and Rnai Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 11. Mrna Vaccines and Rnai Therapeutics Market Size, for Iv Infusion, by Region, 2021-2031 ($Million)
Table 12. Mrna Vaccines and Rnai Therapeutics Market for Iv Infusion by Country, 2021-2031 ($Million)
Table 13. Mrna Vaccines and Rnai Therapeutics Market Size, for Subcutaneous, by Region, 2021-2031 ($Million)
Table 14. Mrna Vaccines and Rnai Therapeutics Market for Subcutaneous by Country, 2021-2031 ($Million)
Table 15. Global Mrna Vaccines and Rnai Therapeutics Market, by End-user, 2021-2031 ($Million)
Table 16. Mrna Vaccines and Rnai Therapeutics Market Size, for Research Institutes, by Region, 2021-2031 ($Million)
Table 17. Mrna Vaccines and Rnai Therapeutics Market for Research Institutes by Country, 2021-2031 ($Million)
Table 18. Mrna Vaccines and Rnai Therapeutics Market Size, for Hospitals and Clinics, by Region, 2021-2031 ($Million)
Table 19. Mrna Vaccines and Rnai Therapeutics Market for Hospitals and Clinics by Country, 2021-2031 ($Million)
Table 20. Mrna Vaccines and Rnai Therapeutics Market, by Region, 2021-2031 ($Million)
Table 21. North America Mrna Vaccines and Rnai Therapeutics Market, by Disease Type, 2021-2031 ($Million)
Table 22. North America Mrna Vaccines and Rnai Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 23. North America Mrna Vaccines and Rnai Therapeutics Market, by End-user, 2021-2031 ($Million)
Table 24. North America Mrna Vaccines and Rnai Therapeutics Market, by Country, 2021-2031 ($Million)
Table 25. U.S. Mrna Vaccines and Rnai Therapeutics Market, by Disease Type, 2021-2031 ($Million)
Table 26. U.S. Mrna Vaccines and Rnai Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 27. U.S. Mrna Vaccines and Rnai Therapeutics Market, by End-user, 2021-2031 ($Million)
Table 28. Canada Mrna Vaccines and Rnai Therapeutics Market, by Disease Type, 2021-2031 ($Million)
Table 29. Canada Mrna Vaccines and Rnai Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 30. Canada Mrna Vaccines and Rnai Therapeutics Market, by End-user, 2021-2031 ($Million)
Table 31. Mexico Mrna Vaccines and Rnai Therapeutics Market, by Disease Type, 2021-2031 ($Million)
Table 32. Mexico Mrna Vaccines and Rnai Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 33. Mexico Mrna Vaccines and Rnai Therapeutics Market, by End-user, 2021-2031 ($Million)
Table 34. Europe Mrna Vaccines and Rnai Therapeutics Market, by Disease Type, 2021-2031 ($Million)
Table 35. Europe Mrna Vaccines and Rnai Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 36. Europe Mrna Vaccines and Rnai Therapeutics Market, by End-user, 2021-2031 ($Million)
Table 37. Europe Mrna Vaccines and Rnai Therapeutics Market, by Country, 2021-2031 ($Million)
Table 38. Germany Mrna Vaccines and Rnai Therapeutics Market, by Disease Type, 2021-2031 ($Million)
Table 39. Germany Mrna Vaccines and Rnai Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 40. Germany Mrna Vaccines and Rnai Therapeutics Market, by End-user, 2021-2031 ($Million)
Table 41. France Mrna Vaccines and Rnai Therapeutics Market, by Disease Type, 2021-2031 ($Million)
Table 42. France Mrna Vaccines and Rnai Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 43. France Mrna Vaccines and Rnai Therapeutics Market, by End-user, 2021-2031 ($Million)
Table 44. U.K. Mrna Vaccines and Rnai Therapeutics Market, by Disease Type, 2021-2031 ($Million)
Table 45. U.K. Mrna Vaccines and Rnai Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 46. U.K. Mrna Vaccines and Rnai Therapeutics Market, by End-user, 2021-2031 ($Million)
Table 47. Italy Mrna Vaccines and Rnai Therapeutics Market, by Disease Type, 2021-2031 ($Million)
Table 48. Italy Mrna Vaccines and Rnai Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 49. Italy Mrna Vaccines and Rnai Therapeutics Market, by End-user, 2021-2031 ($Million)
Table 50. Spain Mrna Vaccines and Rnai Therapeutics Market, by Disease Type, 2021-2031 ($Million)
Table 51. Spain Mrna Vaccines and Rnai Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 52. Spain Mrna Vaccines and Rnai Therapeutics Market, by End-user, 2021-2031 ($Million)
Table 53. Rest of Europe Mrna Vaccines and Rnai Therapeutics Market, by Disease Type, 2021-2031 ($Million)
Table 54. Rest of Europe Mrna Vaccines and Rnai Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 55. Rest of Europe Mrna Vaccines and Rnai Therapeutics Market, by End-user, 2021-2031 ($Million)
Table 56. Asia-Pacific Mrna Vaccines and Rnai Therapeutics Market, by Disease Type, 2021-2031 ($Million)
Table 57. Asia-Pacific Mrna Vaccines and Rnai Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 58. Asia-Pacific Mrna Vaccines and Rnai Therapeutics Market, by End-user, 2021-2031 ($Million)
Table 59. Asia-Pacific Mrna Vaccines and Rnai Therapeutics Market, by Country, 2021-2031 ($Million)
Table 60. China Mrna Vaccines and Rnai Therapeutics Market, by Disease Type, 2021-2031 ($Million)
Table 61. China Mrna Vaccines and Rnai Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 62. China Mrna Vaccines and Rnai Therapeutics Market, by End-user, 2021-2031 ($Million)
Table 63. Japan Mrna Vaccines and Rnai Therapeutics Market, by Disease Type, 2021-2031 ($Million)
Table 64. Japan Mrna Vaccines and Rnai Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 65. Japan Mrna Vaccines and Rnai Therapeutics Market, by End-user, 2021-2031 ($Million)
Table 66. India Mrna Vaccines and Rnai Therapeutics Market, by Disease Type, 2021-2031 ($Million)
Table 67. India Mrna Vaccines and Rnai Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 68. India Mrna Vaccines and Rnai Therapeutics Market, by End-user, 2021-2031 ($Million)
Table 69. Australia Mrna Vaccines and Rnai Therapeutics Market, by Disease Type, 2021-2031 ($Million)
Table 70. Australia Mrna Vaccines and Rnai Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 71. Australia Mrna Vaccines and Rnai Therapeutics Market, by End-user, 2021-2031 ($Million)
Table 72. South Korea Mrna Vaccines and Rnai Therapeutics Market, by Disease Type, 2021-2031 ($Million)
Table 73. South Korea Mrna Vaccines and Rnai Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 74. South Korea Mrna Vaccines and Rnai Therapeutics Market, by End-user, 2021-2031 ($Million)
Table 75. Rest of Asia-Pacific Mrna Vaccines and Rnai Therapeutics Market, by Disease Type, 2021-2031 ($Million)
Table 76. Rest of Asia-Pacific Mrna Vaccines and Rnai Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 77. Rest of Asia-Pacific Mrna Vaccines and Rnai Therapeutics Market, by End-user, 2021-2031 ($Million)
Table 78. LAMEA Mrna Vaccines and Rnai Therapeutics Market, by Disease Type, 2021-2031 ($Million)
Table 79. LAMEA Mrna Vaccines and Rnai Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 80. LAMEA Mrna Vaccines and Rnai Therapeutics Market, by End-user, 2021-2031 ($Million)
Table 81. LAMEA Mrna Vaccines and Rnai Therapeutics Market, by Country, 2021-2031 ($Million)
Table 82. Brazil Mrna Vaccines and Rnai Therapeutics Market, by Disease Type, 2021-2031 ($Million)
Table 83. Brazil Mrna Vaccines and Rnai Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 84. Brazil Mrna Vaccines and Rnai Therapeutics Market, by End-user, 2021-2031 ($Million)
Table 85. Saudi Arabia Mrna Vaccines and Rnai Therapeutics Market, by Disease Type, 2021-2031 ($Million)
Table 86. Saudi Arabia Mrna Vaccines and Rnai Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 87. Saudi Arabia Mrna Vaccines and Rnai Therapeutics Market, by End-user, 2021-2031 ($Million)
Table 88. South Africa Mrna Vaccines and Rnai Therapeutics Market, by Disease Type, 2021-2031 ($Million)
Table 89. South Africa Mrna Vaccines and Rnai Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 90. South Africa Mrna Vaccines and Rnai Therapeutics Market, by End-user, 2021-2031 ($Million)
Table 91. Rest of LAMEA Mrna Vaccines and Rnai Therapeutics Market, by Disease Type, 2021-2031 ($Million)
Table 92. Rest of LAMEA Mrna Vaccines and Rnai Therapeutics Market, by Route of Administration, 2021-2031 ($Million)
Table 93. Rest of LAMEA Mrna Vaccines and Rnai Therapeutics Market, by End-user, 2021-2031 ($Million)
Table 94. Alnylam Pharmaceuticals: Company Snapshot
Table 95. Alnylam Pharmaceuticals: Operating Segments
Table 96. Alnylam Pharmaceuticals: Product Portfolio
Table 97. Alnylam Pharmaceuticals: Net Sales
Table 98. Alnylam Pharmaceuticals: Key Stratergies
Table 99. Biontech Ag: Company Snapshot
Table 100. Biontech Ag: Operating Segments
Table 101. Biontech Ag: Product Portfolio
Table 102. Biontech Ag: Net Sales
Table 103. Biontech Ag: Key Stratergies
Table 104. Curevac Ag: Company Snapshot
Table 105. Curevac Ag: Operating Segments
Table 106. Curevac Ag: Product Portfolio
Table 107. Curevac Ag: Net Sales
Table 108. Curevac Ag: Key Stratergies
Table 109. Etherna Immunotherapies: Company Snapshot
Table 110. Etherna Immunotherapies: Operating Segments
Table 111. Etherna Immunotherapies: Product Portfolio
Table 112. Etherna Immunotherapies: Net Sales
Table 113. Etherna Immunotherapies: Key Stratergies
Table 114. Ethris GmbH: Company Snapshot
Table 115. Ethris GmbH: Operating Segments
Table 116. Ethris GmbH: Product Portfolio
Table 117. Ethris GmbH: Net Sales
Table 118. Ethris GmbH: Key Stratergies
Table 119. In-Cell-Art: Company Snapshot
Table 120. In-Cell-Art: Operating Segments
Table 121. In-Cell-Art: Product Portfolio
Table 122. In-Cell-Art: Net Sales
Table 123. In-Cell-Art: Key Stratergies
Table 124. Moderna Therapeutics: Company Snapshot
Table 125. Moderna Therapeutics: Operating Segments
Table 126. Moderna Therapeutics: Product Portfolio
Table 127. Moderna Therapeutics: Net Sales
Table 128. Moderna Therapeutics: Key Stratergies
Table 129. Sangamo Therapeutics, Inc.: Company Snapshot
Table 130. Sangamo Therapeutics, Inc.: Operating Segments
Table 131. Sangamo Therapeutics, Inc.: Product Portfolio
Table 132. Sangamo Therapeutics, Inc.: Net Sales
Table 133. Sangamo Therapeutics, Inc.: Key Stratergies
Table 134. Sanofi Ag: Company Snapshot
Table 135. Sanofi Ag: Operating Segments
Table 136. Sanofi Ag: Product Portfolio
Table 137. Sanofi Ag: Net Sales
Table 138. Sanofi Ag: Key Stratergies
Table 139. Scm Life Sciences (Argos Therapeutics, Inc. ): Company Snapshot
Table 140. Scm Life Sciences (Argos Therapeutics, Inc. ): Operating Segments
Table 141. Scm Life Sciences (Argos Therapeutics, Inc. ): Product Portfolio
Table 142. Scm Life Sciences (Argos Therapeutics, Inc. ): Net Sales
Table 143. Scm Life Sciences (Argos Therapeutics, Inc. ): Key Stratergies
Table 144. Sarepta Therapeutics: Company Snapshot
Table 145. Sarepta Therapeutics: Operating Segments
Table 146. Sarepta Therapeutics: Product Portfolio
Table 147. Sarepta Therapeutics: Net Sales
Table 148. Sarepta Therapeutics: Key Stratergies
Table 149. Arcturus Therapeutics: Company Snapshot
Table 150. Arcturus Therapeutics: Operating Segments
Table 151. Arcturus Therapeutics: Product Portfolio
Table 152. Arcturus Therapeutics: Net Sales
Table 153. Arcturus Therapeutics: Key Stratergies
Table 154. Ionis Pharmaceuticals, Inc: Company Snapshot
Table 155. Ionis Pharmaceuticals, Inc: Operating Segments
Table 156. Ionis Pharmaceuticals, Inc: Product Portfolio
Table 157. Ionis Pharmaceuticals, Inc: Net Sales
Table 158. Ionis Pharmaceuticals, Inc: Key Stratergies
Table 159. Nutcracker: Company Snapshot
Table 160. Nutcracker: Operating Segments
Table 161. Nutcracker: Product Portfolio
Table 162. Nutcracker: Net Sales
Table 163. Nutcracker: Key Stratergies
Table 164. Tiba Biotech: Company Snapshot
Table 165. Tiba Biotech: Operating Segments
Table 166. Tiba Biotech: Product Portfolio
Table 167. Tiba Biotech: Net Sales
Table 168. Tiba Biotech: Key Stratergies
List of Figures
Figure 1. Housing Finance Market Segmentation
Figure 2. Housing Finance Market,2021-2031
Figure 3. Housing Finance Market,2021-2031
Figure 4. Top Investment Pockets, by Region
Figure 5. Porter Five-1
Figure 6. Porter Five-2
Figure 7. Porter Five-3
Figure 8. Porter Five-4
Figure 9. Porter Five-5
Figure 10. Top Player Positioning
Figure 11. Housing Finance Market:Drivers, Restraints and Opportunities
Figure 12. Housing Finance Market,By Application,2021(%)
Figure 13. Comparative Share Analysis of Home Purchase Housing Finance Market,2021-2031(%)
Figure 14. Comparative Share Analysis of Refinance Housing Finance Market,2021-2031(%)
Figure 15. Comparative Share Analysis of Home Improvement Housing Finance Market,2021-2031(%)
Figure 16. Comparative Share Analysis of Other Purpose Housing Finance Market,2021-2031(%)
Figure 17. Housing Finance Market,By Providers,2021(%)
Figure 18. Comparative Share Analysis of Banks Housing Finance Market,2021-2031(%)
Figure 19. Comparative Share Analysis of Housing Finance Companies Housing Finance Market,2021-2031(%)
Figure 20. Comparative Share Analysis of Real Estate Agents Housing Finance Market,2021-2031(%)
Figure 21. Comparative Share Analysis of Others Housing Finance Market,2021-2031(%)
Figure 22. Housing Finance Market by Region,2021
Figure 23. U.S. Housing Finance Market,2021-2031($Billion)
Figure 24. Canada Housing Finance Market,2021-2031($Billion)
Figure 25. Germany Housing Finance Market,2021-2031($Billion)
Figure 26. United Kingdom Housing Finance Market,2021-2031($Billion)
Figure 27. France Housing Finance Market,2021-2031($Billion)
Figure 28. Italy Housing Finance Market,2021-2031($Billion)
Figure 29. Spain Housing Finance Market,2021-2031($Billion)
Figure 30. Netherlands Housing Finance Market,2021-2031($Billion)
Figure 31. Rest of Europe Housing Finance Market,2021-2031($Billion)
Figure 32. China Housing Finance Market,2021-2031($Billion)
Figure 33. India Housing Finance Market,2021-2031($Billion)
Figure 34. Japan Housing Finance Market,2021-2031($Billion)
Figure 35. Australia Housing Finance Market,2021-2031($Billion)
Figure 36. Singapore Housing Finance Market,2021-2031($Billion)
Figure 37. Rest of Asia-Pacific Housing Finance Market,2021-2031($Billion)
Figure 38. Latin America Housing Finance Market,2021-2031($Billion)
Figure 39. Middle East Housing Finance Market,2021-2031($Billion)
Figure 40. Africa Housing Finance Market,2021-2031($Billion)
Figure 41. Top Winning Strategies, by Year
Figure 42. Top Winning Strategies, by Development
Figure 43. Top Winning Strategies, by Company
Figure 44. Product Mapping of Top 10 Players
Figure 45. Competitive Dashboard
Figure 46. Competitive Heatmap of Top 10 Key Players
Figure 47. Bank of America Corporation.: Net Sales ,($Billion)
Figure 48. Charles Schwab & Co..: Net Sales ,($Billion)
Figure 49. Citigroup, Inc..: Net Sales ,($Billion)
Figure 50. Credit Suisse.: Net Sales ,($Billion)
Figure 51. Dewan Housing Finance Corporation Limited.: Net Sales ,($Billion)
Figure 52. Goldman Sachs.: Net Sales ,($Billion)
Figure 53. HSBC Group.: Net Sales ,($Billion)
Figure 54. Jpmorgan Chase & Co..: Net Sales ,($Billion)
Figure 55. Lic Housing Finance Limited.: Net Sales ,($Billion)
Figure 56. Lloyd's Banking Group.: Net Sales ,($Billion)
Figure 57. Morgan Stanley.: Net Sales ,($Billion)
Figure 58. Royal Bank of Canada.: Net Sales ,($Billion)
Figure 59. The Royal Bank of Scotland PLC.: Net Sales ,($Billion)
Figure 60. Ubs.: Net Sales ,($Billion)
Figure 61. Wells Fargo.: Net Sales ,($Billion)